L‐CRAMs provide a versatile, long‐acting RNA interference platform that addresses key limitations of existing LNP systems and advances therapeutic RNA delivery.
Abstract
Lipid nanoparticles (LNPs) are state‐of‐the‐art siRNA carriers but are limited by modest RNA loading, inefficient endosomal escape, and short‐lived silencing due to burst release at escape. To overcome these constraints, we developed lipid‐layered core RNA‐assembled nanomodules (L‐CRAMs) that couple a self‐assembled RNA core with fusogenic lipids to enable sustained, high‐capacity siRNA delivery. L‐CRAMs release siRNA gradually, exhibit fusion‐mediated intracellular delivery with limited endo‐lysosomal sequestration, and produce robust silencing across single and multiplexed targets in vitro. Compared with MC3‐LNPs, L‐CRAMs prolonged intracellular gene silencing. Following systemic administration in mice, L‐CRAMs induced potent, durable suppression of the clinically relevant liver gene APOC3, accompanied by reductions in serum triglycerides (TG) and triglyceride‐rich lipoproteins (TRL). By integrating ultra‐high RNA payloads, fusogenic uptake, and programmable multi‐gene targeting, L‐CRAMs provide a versatile, long‐acting RNA interference platform that addresses key limitations of existing LNP systems and advances therapeutic RNA delivery.
ABSTRACT Lipid nanoparticles (LNPs) have enabled the clinical application of RNA therapeutics, including approved mRNA vaccines and siRNA medicines. However, their predominant accumulation in liver after systemic administration and inefficient endosomal escape remain key bottlenecks for productive cytosolic delivery an...
Seong Gi Lim, Min-Ju Lee, Yiming Wang et al.· Advancement of science· 0 citations
This study develops a class of ionizable cholesterol derivatives by conjugating biocompatible dimethylated amino acids to cholesterol through a cleavable linker, thereby integrating the structural role of cholesterol and the pH‐responsive ionization of ions into a single molecule.
Lipid Nanoparticles (LNPs) have emerged as adaptable and effective delivery systems for RNA-based therapies, transforming contemporary medicine. This article covers the design, processes, and therapeutic potential of LNPs for RNA delivery. LNPs improve RNA encapsulation, stability, and targeted cellular delivery. Lipid...
Shayeri Chatterjee Ganguly, Priya Manna, Satadeep Bandyapadhyay et al.· Recent Advances in Drug Deli...· 0 citations
A programmably engineered DNA nanocircuit with cascaded dual‐AND logic gates enables the development of a spatiotemporally controlled siRNA delivery strategy for precision cancer therapy, highlighting the potential of DNA circuits in precision cancer therapy.
Yan Zhao, Yu-Fei Lan, Min-Goo Lee et al.· Advancement of science· 0 citations
Lipid nanoparticles (LNPs) are a clinically validated nonviral platform for the delivery of CRISPR-associated components. Composed of ionizable lipids, phospholipids, cholesterol, and PEG-lipids, LNPs enable the efficient encapsulation, protection, and cytosolic delivery of therapeutic cargo such as DNA, RNA, or protei...
A. Olsen, C. Brandt, Rasmus Karred Larsen et al.· Methods in molecular biology· 0 citations
This synthesis aims to guide formulation scientists, clinician‐scientists, and regulatory professionals in advancing the next generation of LNP‐based precision nanomedicines by linking molecular lipid design to manufacturing scalability, long‐term safety, and equitable access.
T. Ikrar, Wachyudi Muchsin, Alfi Sophian· European Journal of Lipid Sc...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.